Clinical Trial Update: Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia [NA]

View source ↗

Summary

This clinical trial investigates the combination of Romiplostim N01 with Rituximab for primary immune thrombocytopenia that is refractory to oral TPO receptor a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)
• Romiplostim N01 (romiplostim)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Primacy Immune Thrombocytopenia | NA | Status: RECRUITING